Edgewise Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
EWTX$48.74+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
STATEMENTS OF CASH FLOWS
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year ended December 31, | ||||||
| · 2023 · 2022 | ||||||
| Cash flows from operating activities · · · · · | ||||||
| Net loss | | $(100,163) | $(67,640) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | |||
| Depreciation | | | 1,551 | | 368 | |
| Stock-based compensation | | 17,560 | | 10,924 | ||
| Amortization (accretion) of premium (discount) on marketable securities, net | | | (9,517) | | | (543) |
| Amortization of right-of-use asset | | | 181 | | | 170 |
| Changes in assets and liabilities: | | | | |||
| Prepaid expenses and other assets | | (3,553) | | (1,452) | ||
| Accounts payable | | (92) | | 47 | ||
| Accrued compensation | | 1,663 | | 1,235 | ||
| Accrued other expenses and other liabilities | | 526 | | 1,336 | ||
| Lease liability | | (104) | | | 2,920 | |
| Net cash used in operating activities | | (91,948) | | | (52,635) | |
| | | | | | | |
| Cash flows from investing activities | | | | | ||
| Purchases of marketable securities | | (255,866) | | (292,388) | ||
| Sales of marketable securities | | | 20,118 | | | 30,574 |
| Maturities of marketable securities | | | 344,379 | | | 196,783 |
| Purchases of property and equipment | | (5,745) | | (5,546) | ||
| Net cash provided by (used in) investing activities | | 102,886 | | (70,577) | ||
| | | | | | | |
| Cash flows from financing activities | | | ||||
| Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering costs | | | 52,618 | | | 129,165 |
| Exercise of stock options | | 117 | | 405 | ||
| Payment of deferred offering costs | | | (165) | | | (251) |
| Proceeds from Employee Stock Purchase Plan | | | 596 | | | 320 |
| Net cash provided by financing activities | | 53,166 | | 129,639 | ||
| | | | | | | |
| Net change in cash and cash equivalents | | 64,104 | | 6,427 | ||
| Cash and cash equivalents at beginning of period | | 21,993 | | 15,566 | ||
| Cash and cash equivalents at end of period | | $86,097 | | $21,993 | ||
| Supplemental disclosures of non-cash investing and financing activities: | | | ||||
| Right-of-use asset obtained in exchange for new operating lease liability, net of tenant improvement receivable | | $1,110 | | $1,488 | ||
| Property and equipment purchases included in accounts payable and accrued other expenses | | $227 | | $2,510 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.